BIOHK2020Biotech Kaleidoscope - Infinite Possibilities
1
Foreword
BIOHK will bring together the world’s leading, established
and most innovative stakeholders in biotech, pharma and
finance as they collaborate in exploring the future of Hong
Kong’s role as a Biotech hub for the advancement of
Biotech benefits worldwide. BIOHK is expected to
become a signature event in Hong Kong.
2
Why Biotech in Hong Kong ?
Historically, the cyclical nature of biotech revolutions brought
a fresh surge of innovation every two decades.
Hong Kong is at the nexus of converging goals and visions
between key regional and global industry, finance, academic,
research and innovation sectors.
This is the right moment to capitalize on the Hong Kong
Special Administrative Region’s unique position as a strategic
global hub for biotech.
◆ Year 1980 in USA ◆ Year 2000 in Europe◆ Year 2020 in Hong Kong
▪ President Xi Jinping directed state agencies to help
Hong Kong become an international innovation hub
▪ Hong Kong possesses extensive experience in
commercializing innovative technology for industrial
application and branding & marketing
▪ See more details in Appendix V
3
Hong Kong Being the Key Strategic Role
▪ World-class R&D capability
▪ World’s top three Financial Centers for Venture Capital
▪ Gateway to vast China market
▪ Strong International Investor Base
▪ See more in Appendix VI
4
Hong Kong Offers
5
Exhibition Conference & Pitch Session
One2One Partnering Welcome Reception
Public Lectures Biotech Night in Lan Kwai Fong
Greater Bay Area Tour Gala Dinner & Awards Ceremony
Dates: 19-22/08/2020 (Wednesday – Saturday)
Venue: AsiaWorld-Expo (tentative)
Exhibition: Around 300 exhibition booths (could be more)
Speakers: Over 150
Expected visitors: Over 7,000
Highlights:
BIOHK2020 – Event Details
Exhibition> Showcase and Connect
Showcase and Connect your company to the international
biotech scene and vast China market for trading and
collaboration opportunities.
Conference> Share and Inspire
Share and Inspire through invaluable discussions about the
latest regional and international research findings and
industry trends.
One2One Partnering> Promote and Establish
Promote and Establish your company as ‘one to watch’ in
the biotech marketplace by identifying and meeting
prospective partners.
6
BIOHK2020 - Event Highlights
Reach the leading, established, most innovative and freshest voices in Big
Health Industry, Biotech, Drug Development and Pharma. Pitch and Connect
your company to the international biotech scene and vast China market for
trading and collaboration opportunities.
▪ Present your Brand and Innovations
▪ Reinforce Positioning
▪ Build Brand Awareness
▪ Extend Brand Reach
▪ Advertise to Target Market(s)
▪ Valuable Face-Time
▪ Connections with Related Parties
▪ Extend Visibility
▪ Expand Customer Base
▪ Business to Business Trading
7
Exhibition - Showcase and Connect
Enhance Your Awareness
A platform for in-depth discussions and mapping of the latest regional
and international industry and research findings and trends.
8
Gain Unique Insights
Attain the Latest Know-how
Biotech seminars
Conference - Share and Inspire
Sessions will showcase leading thinkers, international scientists, entrepreneurs and
investors from diverse disciplines coming together to exchange research findings, ideas
and professional development experiences across a wide range of topics in interactive
sessions, panel discussions and podium talks.
We are expecting more than 7,000 participants, including over 150 speakers across
multiple panel sessions
*Conference Topics see appendix IV
9
Keynote Speakers
HAN Ji ShengDirector, Institute of Neuroscience, Peking University
LEUNG Chun YingVice Chairman, National Committee of the CPPCC
SONG RuilinChairman, China Pharmaceutical Innovation and Research Development Association
WANG YuFormer Director General, Chinese Center for Disease Control and Prevention (China CDC)
YANG Huan MingCo-founder, Director and Chairman of BGI Group
ZHAN Qi MinExecutive Vice President, Peking University
BIRUKOV G. KonstantinAnesthesiology Endowed Professor, Entrepreneurial Research and Professor of Physiology
GLASS David, JonathanVice President, Research, Regeneron Pharmaceuticals, Inc.
GRAY NancyPresident & CEO, The Gordon Research Conferences
JOHNSON E. BruceChief Clinical Research Officer, Dana-Farber Cancer Institute
YUNG Wai-Kwan, AlfredProfessor, Department of Neuro-Oncology, University of Texas, MD Anderson Cancer Center
ZHAO Guo PingProfessor, Shanghai Institute for Biological Sciences, CAS
ZHOU Guo Ying, GracePresident, Shenzhen International Institute for Biomedical Research
Speakers
**Further Speakers to be Announced
Explore and secure collaborative partnerships and cross-border possibilities.
Promote and establish your company as “one to watch” in the biotech marketplace
by identifying and meeting prospective partners.
Network with industry practitioners,academicians, reputable biopharma firmsand educational institutions
Spot your prospective partners – investors,analysts and partnering companies
Form valuable partnerships with leadingbiotech firms
Meet and greet with high-level executives
Build promising partnerships in a broad-spectrum marketplace
Investors have opportunities to extend business propositions to inventors
Explore Hong Kong as the home for your next business or start-up
10
One2One Partnering - Promote and Establish
Biotech Night in
Lan Kwai Fong > Social Networking
One of Hong Kong’s most popular nightlife hot spots and home to
over 90 restaurants and bars. Join us on Friday night before the
final day of the convention to unwind, celebrate new partnerships
or make new friends.
Greater Bay Area Tour> More Opportunities in GBA
Out of China’s 199 science parks, 111 are biotechnology-related,
with 93 concentrated in the Guangzhou area. Get an in depth look
into this high-tech research and manufacturing epicentre by joining
our Greater Bay Area tour.
Gala Dinner> Awards Ceremony
Held in the last day evening, it is expected government head,
executives, professionals and guests from Hong Kong, GBA and
Central Federal Government, together with BIOHK Convention
delegates will participate in this grand event.
11
BIOHK2020 - Side Event Highlights
InvestorsBiological and
StartupsHealth and
medical industry
• Biotech Entrepreneurs
• CRO
• CMO
• Academia
• R&D Organizations
• Government
• Research Labs
• Leading Consultancy Services
• Science / Industrial Parks
• Incubation Centers
• Clinical & Education Trial Centers
• Diagnostics & Medical Devices
• Biopharmaceutical & Drug Developers
• Clinical Research & Lab Services
• Regenerative Medicine
• Agriculture and Fishery Biotechnology
• Bio manufacturing Platform Technologies
• Genomics / Genetics
• Marine Biotechnology
• Generic Drugs, API and Intermediates
• Smart Hospitals
• Investment, Legal and Financial Services
• And more…
12
BIOHK2020 - Target Audience
BIOHK2020 - Organizing Committees (1)
BASujuanPresident and CEO,
National Foundation for Cancer Research
HAO MarthaBusiness Consultant of Wise
Ally Holding Ltd.
CHAN Sabrina
Senior Executive Director, Hong Kong Association of
the Pharmaceuticals Industry
CHAU Chi Wai, WiltonChairman, Pan Asia Venture
Development Platform (PAVD)
CHEN Ping
Founding Partner, AusvicCapital Limited
CHEN Wei Jie, Danny
Investment Director, Affix Capital
CHUNG Pui Sing, JohnFormer superintendent,
Hong Kong Police Force
HAU Desmond
CEO, Pangenia Inc and DiagCor Life Science Ltd.
HSIAO Wen Luan, WendyProfessor, State Key Laboratory of
Quality Research in Chinese Medicine,Macau University of
Science and Technology
HU Charles
Founder, Ryoden Medical Holdings Limited and Co-
founder, Incando Therapeutics
JIANG ClaireCEO, Queens (Shenzhen) Biotechnology Co., Ltd.
JIANG Ru Hong
Founder, CEO, President and Director,
ASC Therapeutics, Inc.
JE Simon
Chairman of the Board, Great Treasure International / Galaxy
Treasure Group
JIN Kewen
Managing Partner & Co-founder, Serica Capital
LAW Philip
Technology, Media and Technology Leader, Hong Kong,
Deloitte
LE DEU Franck
Senior Partner, Head of Greater China, McKinsey & Company
LEE Tin LapAssociate Professor, School of Biomedical Sciences, Faculty of
Medicine, The Chinese Universityof Hong Kong
LEUNG Yun Chung, Thomas
Lo Ka Chung Charitable Foundation Professor in Pharmaceutical
Sciences Professor and DoULS
LI JamesPresident, Li Law Inc.
LI Ronald
Director, Ming-Wai Lau Centre for Reparative Medicine, HK node,
Karolinska Institutet (KI), Sweden.
LEUNG Chuen YanVice President, Portfolio
Management and Research
LI Ying
Chair Professor of Neuroscience,
City University of Hong Kong
LIN MindinCEO & Editor in Chief,
Global Bio & InvestmentMonthly
LI Xiao Yi, Benjamin
CEO, Lee's Pharmaceutical Holdings
Limited
LO KittyChairman and CEO,
Finet Group Ltd.
LO Yuk Lam
Chairman, Food and Environmental Hygiene, Food and Health Bureau,
Government Secretariat HKSAR
LU Ming Hua
Founding Partner, eChinaHealth
LIU Andy
CEO, CW Data Technologies
13
BIOHK2020 - Organizing Committees (2)
14
MOK Kin Lun, JohnChairman of AML Holdings
Limited
NEARING Kimberly
Board of Directors, The BayHelixGroup
NGUYENPHUOC DonnaPartner, SPARQ Capital
MONTELIUS Lars
Director General, International Iberian Nanotechnology Laboratory
PAN Wendy, JD
Board of Directors, The BayHelix Group
PEI Duan QingPrinciple Investigator and AcademicDirector at the Guangzhou Institutesof Biomedicine and Health (GIBH),
Chinese Academy of Sciences
ORR KevinVice President, Winner
Medical Group
SEGERBLOM BjornHonorary Chairman and Hong Kong Representative, International Iberian
Nanotechnology Laboratory
SHANG Hai LongManaging Director,
Sense Time Hong Kong
SHI Victor
CEO, Adicon Clinical Laboratories
SUN NanDeputy Inspector, ShenzhenAssociation for Science and
Technology
QIAN Pei Yuan
Head and Chair Professor, Department of Ocean Science,
Hong Kong University of Science and Technology
SIU Eric
Chairman of the Hong Kong Center, Macau International Healthcare Think
Tank
SUN FeiAssistant Professor, Chemical and Biological Engineering, The Hong Kong University of Science and
Technology
SUN-Hoffman Lin Head of the North California
Division, BayHelix
TANG C. Mark
Managing Director, Good Health Capital (New York)
TIAN Yao LinCEO, Shenzhen Govita
Medical Laboratory
TSUI Victor
Chief Operating Officer, Powder Pharmaceuticals
Incorporated
UHLEN MathiasPresident, European
Federation of Biotechnology
TSIM Wah Keung, KarlDirector, Centre for Chinese
Medicine R & D
WAN Mu MakiImmediate Past President,
Rotary Club Kowloon Golden Miles
WANG Jing
Centre for Advanced Measurement Science, National Institute of Metrology, China
WANG YitaoDirector, Institute of
Chinese Medical Sciences
WONG AnnyCEO, AlphaSmart World Limited
WONG Bing LouAdjunct Professor, Department
of Biochemistry, Chinese University of Hong Kong
WONG Taam Chi Woon, VivianHon Professor, School of
Chinese Medicine, The University of Hong Kong
WAN Mu Maki
Assistant Professor, Division of Life Science, The Hong Kong
University of Science and Technology
XIE Jia Sheng
Director & Executive President, Guangdong Medical Valley
(GDMV)
BIOHK2020 - Organizing Committees (3)
XIE Min, RobertCEO, Asia Investment Fund
Management Limited
YANG HaidingExecutive Director and Medical Team Leader of
Cathy Capital
YANG Meng Su, MichaelHead and Yeung Kin Man Chair
Professor, Department of BiomedicalSciences, City University of Hong Kong
YANG RayPartner, Marathon Venture Partners
YANG SteveChief Business Officer &Executive Vice President,WuXi AppTec Co., Ltd.
YU DuncanPresident, MGI
YUNG Kin Lam, KenProfessor and Associate Head,
Faculty of Science,Hong Kong Baptist University
ZHANG Jimmy
Founding Member and Former Chairman of
BayHelix Group
ZHOU Guo Ying, Grace
President, Shenzhen International Institute for Biomedical Research
15
BIOHK2020 Operation Team
17
Nancy CHUENCHAI
Project OfficerHong Kong BiotechnologyOrganization
BSc (Hons) in Conventionand Event ManagementSchool of Hotel andTourism ManagementThe Hong Kong PolytechnicUniversity
Dior LAI
Project OfficerHong Kong BiotechnologyOrganization
BSc (Hons) in Conventionand Event ManagementSchool of Hotel and TourismManagementThe Hong Kong PolytechnicUniversity
George CHAN
Management InformationSystems EngineerHong Kong BiotechnologyOrganization
BEng in Computer ScienceHong Kong University ofScience and Technology
Lori TSANG
Marketing OfficerHong Kong Biotechnology Organization
BA (Hons) Marketing ManagementLeeds Metropolitan University
Louvinia WONG
Project OfficerHong Kong BiotechnologyOrganization
Biological Sciences BSc (Hons) (Physiology with Pharmacology and Neuroscience)University of Leicester
16
v
Organizers
全面展會管理
Co-organizers
17
Diamond Sponsors
18
Special Supporting Organizations
Supporting Organizations
19
Global Partners
20
Official Carrier
21
Official Hotel Partner
Media Partners
Conclusion
BIOHK2020 will open a new era in biotechnology in
Hong Kong.
Join us at this event to witness the start of a new
wave of innovations that will benefit well-being
worldwide.
22
Thank You!
Contact
Website: bio-hk.com Email: [email protected] Tel: +852 2799 7688 Fax: +852 2111 9762
Scan and Find us
Please contact us and we will be happy to help you to
plan your BIOHK2020 experience!
hkbiohkbio-orgBIOHK202023
Appendix
24
Hong Kong Biotechnology Organization (HKBIO) established in 2010 by reputable industry
and esteemed academic representatives, is a non-profit organization which continuously
strives to promote Hong Kong as the biotech hub of Asia. HKBIO has organized and
sponsored several successful events in the past that highlighted the substantial potential of
Hong Kong’s Biotechnology sector.
The BayHelix Group is a non-profit professional organization of business leaders with a
mission to shape the growth of the life sciences and healthcare industry. Founded in 2001
in the San Francisco Bay Area, BayHelix has grown to over 800 members globally with a
strong presence in China and the US. BayHelix aspires to foster and create business
opportunities, supply and nurture leaders for the community, and network and share
information and experience among its members.
25
Appendix I:
About the Organizers
HKBIO's Past Events
2018 Hong Kong Biotech Horizons
A mobile conference with the aim of promoting biotech and connecting professionals from a cross section
of industries to create a diverse network that can foster the biotech industry’s development and innovation.
2017 Hong Kong Biotech Horizons
“Global Congress on Biotechnology: Diagnostics and Therapeutics” brought together
communities of scientific researchers, technology developers and entrepreneurs seeking progress in
translational science.
HKBIO Horizon Series
12th International Conference on Brain Energy Metabolism-linked leading experts and young, emerging neuroscientists worldwide, all interested in diverse aspects of brain energy metabolism.
HKBIO Cancer Research FundDedicated to furthering the cause of preventing and curing cancer by promoting clinical cancer research in Hong Kong and China.
26
Appendix II:
About HKBIO
Out of China’s 199 science parks, 111 arebiotechnology parks, with 93 concentrated in theGuangzhou area.
Some USD45 billion was invested in biotech companies inChina between 2014-2017 – more than USD12 billion of itcoming from Chinese venture capital and other private firms.
China’s DNA sequencing market is expected to grow to 18.3billion RMB by 2022 from 7.2 billion RMB last year, greatlysurpassing the overall global market because of the country’srising income and growing investments in health careinfrastructure.
Hong Kong Stock Exchange’s biggest listing reform in 25 years(effective 30 April 2018) saw the establishment of a newBiotech chapter allowing biotech companies that are pre-revenue or insufficiently profitable to be listed — transformingHong Kong into the world’s second largest biotechnology listingplatform.
Out of the top Asia-Pacific IPOs in 2016, four of the top fivewere China based biotech companies.
Guangdong, Hong Kong and Macao – (key regions in theGreater Bay Area (GBA) established in 2017) promoted jointand coordinated regional economic development.
27
Appendix III:
Biotechnology Trends in 2020
• 5G + Data Transmission
• AI + Biotech
• Anti-ageing
• Antibiotics & Antimicrobial Resistance
• Applications of Bioengineering
• Bioethics, Law & Investment
• Biotech in Guangdong-HK-Macau GBA
• Biotech in Society and Culture
• Biotech IPO + HKEX
• Block Chain + Biotech
• Business Development & Emerging
• Opportunities in Biotech
• Cancer Therapies
• Cardiovascular Diseases, Therapies & Diagnostics
28
• Clinical Trials
• Diagnostics & Medical Devices
• Digitization of Healthcare
• Environmental Biotechnology
• Genome Editing and Gene Therapy
• Glioblastoma
• Global Cell & Gene Therapeutics and Regulatory Trends
• Infectious Diseases and Vaccines
• Intellectual Property Rights
• International Strategic Perspectives
• Lab-on-a-chip
• Marine Biotechnology
• Medical Device Market Penetration
• Microbiome & Probiotics
• Modernization of Chinese Medicine
• New Drug Discovery
• New Therapies
• Oncology
• One Belt One Road
• Pharma
• Precision Medicine and Big Data
• Present and Future Bioethics
• Public Health
• Rare Diseases
• Regenerative Medicine & Immunology
• Stem Cell Research
• Translational Medical Genomics
• And More…
Appendix IV: Topics for the Convention
▪ Hong Kong Exchanges and Clearing Limited has enabled pre-revenue biotech companies to be listed on the Main Board – a milestone in stock market history
▪ Innovation and Technology (I&T) fund has financed over 540 biotech projects and aims to attract more world-class scientific research institutions & technology enterprises
▪ About 1,300 I&T companies and “incubates” have established themselves in the Hong Kong Science Park (HKSP) and Cyberport
▪ Currently, the city has approximately 250-300 biotech-related companies
▪ Hong Kong is a preferred destination for multinationals to set up offices and regional headquarters
▪ Hong Kong’s start-up scene has experienced phenomenal growth in recent years
▪ Several incubators and accelerators offer start-ups comprehensive incubation programs to promote the local biotech scene
29
Appendix V:Hong Kong Being the Key Strategic Role
▪ Active entrepreneurial ecosystem
▪ Free & open economy
▪ Gateway to vast China market
▪ Excellent fund-raising platform
▪ Established financial & legal systems
▪ Sound regulatory regime
▪ Transparent vetting process
▪ IP protection
▪ Business friendly taxes
▪ Innovation & Technology (I&T) fund
▪ Reputable quality control & assurance
▪ A supportive government
30
Appendix VI: Hong Kong Offers